>> Today: Thursday, 02 September, 2010
Site Map  Site Map    Contact Us  Contact Us    NGF Medical Board  NGF Medical Board    Home  Home      
800-504-3189
Help us to help others
a world of hope for families and
individuals with Gaucher Disease

Gaucher Disease

Gaucher Disease is an autosomal recessive disease and the most prevalent Lysosomal Storage Disorder (LSD), with an incidence of about 1 in 20,000 live births. Despite the fact that Gaucher Disease consists of a phenotype, with varying degrees of severity, it has been sub-divided in three subtypes according to the presence or absence of neurological involvement. It is also the most common genetic disease affecting Ashkenazi Jewish people (Eastern, Central and Northern European ancestry), with a carrier frequency of 1 in 10 (Dr. John Barranger and Dr. Ed Ginns 1989). This panethnic disease involves many organ systems, such as liver, spleen, lungs, brain, metabolism and bone marrow.

Gaucher Disease results from a specific enzyme deficiency in the body, caused by a genetic mutation received from both parents. The disease course is quite variable, ranging from no outward symptoms to severe disability and death. Testing, through a simple blood test, is available to identify potential parents who are carriers of the gene and to accurately diagnose those people who have the disease. Fortunately, effective treatments are available for some variants of the Disease. Learn more about Gaucher Disease by clicking on a link below:

Prevalence | Symptoms | Testing | Treatments | Clinical Course

Who we are

The National Gaucher Foundation (NGF), a non-profit organization established in 1984, has funded millions of dollars toward the cause, treatments and cure for Gaucher Disease. We are an objective, independent voice of the Gaucher community, dedicated to providing leadership, outreach and innovative thinking. We offer a wide range of programs and resources to meet the ever-increasing needs of individuals and families affected by this disease.

What we do

The NGF funds research, grants financial assistance, promotes education and awareness, supports legislation and provides vital programs. Through our National Gaucher Care Foundation, the CARE Program and the Care+Plus Program, we extend critical financial assistance to individuals with Gaucher Disease. Supporting medical and lay-community outreach, we host live Webinars, national conferences and patient forums. Additionally, our national and regional marketing programs promote ongoing awareness of Gaucher disease.

For more information, contact ngf@gaucherdisease.org or call
800-504-3189

National Gaucher Foundation has received the coveted four-star rating from Charity Navigator for 2007 National Gaucher Foundation is a member of Independent Charities Of America Jewish Genetic Disease Consortium Member

 

What's New?

2010 Gaucher Conference

NGF members get $35 discount

• NGF Town Hall Meeting,
August 11, 2010

- Listen to Replay at Toll Free:
800-937-6972 or Toll: 402-220-3138
Expires September 11, 2010.

• NGF Members Only!

- Summer 2010 Newsletter Now Available Online

• Gaucher Walk and 5K Run

- 2nd Annual Isabella “Izzy” McFalls Walk and 5K Run, October 16, 2010

• Macy’s Shop for a Cause

- Saturday, October 16, 2010

• How To Talk To Your Family About Gaucher Disease

- Free booklet developed and produced by the Genetic Disease Alliance in collaboration with Genzyme

• Gaucher disease on TV

- Healthy Body, Healthy Mind
Episode 1603

Gaucher disease: a Mysterious Genetic Disorder. This program explores the history of this condition and features patients who talk about their struggles with Gaucher Disease. Also highlighted are the new treatments that are offering hope for people living with this mysterious condition

• Genzyme

• Cerezyme
- 8/23/10 Supply of Cerezyme Update
- 8/23/10 Cerezyme Emergency Access Program
- US Cerezyme Request Form For Physicians

• Eliglustat tartrate
- Genzyme enrolling patients in the largest Gaucher clinical program to date

• Protalix BioTherapeutics

- 7/21/10 Protalix Receives PDUFA Date for taliglucerase alfa

• Shire

- 8/26/10 European Approval of VPRIV® for the Treatment of Type 1 Gaucher Disease
- 7/1/10 Continuous Improvements in Bone Mineral Density for VPRIV®

American Association of Webmasters - Gold Web Award
 Disclaimer | Privacy Policy | Return Policy Copyright © 2010 National Gaucher Foundation All Rights Reserved.  

National Gaucher Foundation

2227 Idlewood Road, Suite 6
Tucker, GA 30084
800-504-3189